<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">F1000Res</journal-id>
<journal-id journal-id-type="iso-abbrev">F1000Res</journal-id>
<journal-id journal-id-type="pmc">F1000Research</journal-id>
<journal-title-group>
<journal-title>F1000Research</journal-title>
</journal-title-group>
<issn pub-type="epub">2046-1402</issn>
<publisher>
<publisher-name>F1000Research</publisher-name>
<publisher-loc>London, UK</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28663780</article-id>
<article-id pub-id-type="pmc">5473405</article-id>
<article-id pub-id-type="doi">10.12688/f1000research.11110.1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
<subj-group>
<subject>Articles</subject>
<subj-group>
<subject>Cell Signaling</subject>
</subj-group>
<subj-group>
<subject>Developmental &amp; Pediatric Neurology</subject>
</subj-group>
<subj-group>
<subject>Epilepsy</subject>
</subj-group>
<subj-group>
<subject>Neurobiology of Disease &amp; Regeneration</subject>
</subj-group>
<subj-group>
<subject>Neuronal Signaling Mechanisms</subject>
</subj-group>
<subj-group>
<subject>Neuropharmacology &amp; Psychopharmacology</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND)</article-title>
<fn-group content-type="pub-status">
<fn>
<p>[version 1; referees: 3 approved]</p>
</fn>
</fn-group>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gipson</surname>
<given-names>Tanjala T.</given-names>
</name>
<xref ref-type="corresp" rid="c1">a</xref>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Johnston</surname>
<given-names>Michael V.</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3701-6028</contrib-id>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<aff id="a1">
<label>1</label>Boling Center for Developmental Disabilities, LeBonheur Children’s Hospital, University of Tennessee Health Sciences Center, Memphis, TN, USA</aff>
<aff id="a2">
<label>2</label>Kennedy Krieger Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA</aff>
</contrib-group>
<author-notes>
<corresp id="c1">
<label>a</label>
<email xlink:href="mailto:bcddndd@uthsc.edu">bcddndd@uthsc.edu</email>
</corresp>
<fn fn-type="COI-statement">
<p>
<bold>Competing interests: </bold>The authors declare that they have no competing interests.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>9</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>6</volume>
<elocation-id>F1000 Faculty Rev-859</elocation-id>
<history>
<date date-type="accepted">
<day>7</day>
<month>6</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2017 Gipson TT and Johnston MV</copyright-statement>
<copyright-year>2017</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="f1000research-6-11986.pdf" xlink:type="simple"></self-uri>
<abstract>
<p>Tuberous sclerosis complex (TSC) is a multi-system disorder resulting from mutations in either the
<italic>TSC1</italic> or
<italic>TSC2 </italic>genes leading to hyperactivation of mechanistic target of rapamycin (mTOR) signaling. TSC is commonly associated with autism (61%), intellectual disability (45%), and behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties that are collectively referred to as TSC-associated neuropsychiatric disorders (TAND). More than 90% of children with TSC have epilepsy, including infantile spasms, and early onset of seizures, especially infantile spasms, is associated with greater impairment in intellectual development compared with individuals with TSC without seizures. Development of the mTOR inhibitors everolimus and sirolimus has led to considerable progress in the treatment of renal angiomyolipomata, pulmonary lymphangioleiomyomatosis, and subependymal giant cell astrocytomas in the brain. However, similar therapeutic progress is needed in the treatment of TAND.</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>TSC1</kwd>
<kwd>TSC2</kwd>
<kwd>neuropsychiatric disorder</kwd>
<kwd>tuberous sclerosis complex</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement>
</funding-group>
</article-meta>
<notes>
<sec sec-type="editor-note">
<title>Editorial Note on the Review Process</title>
<p>
<ext-link ext-link-type="uri" xlink:href="http://f1000research.com/browse/f1000-faculty-reviews">F1000 Faculty Reviews</ext-link> are commissioned from members of the prestigious
<ext-link ext-link-type="uri" xlink:href="http://f1000.com/prime/thefaculty">F1000 Faculty</ext-link> and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).</p>
<p>The referees who approved this article are: </p>
<list list-content="reviewer-list" list-type="simple">
<list-item>
<p>
<named-content content-type="reviewer-name">Mustafa Sahin</named-content>, Department of Neurology, F.M. Kirby Center for Neurobiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
<fn fn-type="COI-statement"><p>Competing interests: Mustafa Sahin has received research funding from Roche, Novartis, Pfizer and LAM Therapeutics. He has also served as a consultant for Roche and has been on the Scientific Advisory Board for SAGE Therapeutics.</p></fn>
</p>
</list-item>
<list-item>
<p>
<named-content content-type="reviewer-name">Peter Crino</named-content>, Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland, USA
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p>
</list-item>
<list-item>
<p>
<named-content content-type="reviewer-name">Paolo Curatolo</named-content>, Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University of Rome, Rome, Italy
<fn fn-type="COI-statement"><p>No competing interests were disclosed.</p></fn>
</p>
</list-item>
</list>
</sec>
</notes>
</front>
<body>
<p>Tuberous sclerosis complex (TSC) affects 1 out of 6,000 live births and is the second most common neurocutaneous disease (neurofibromatosis is the most common)
<sup><xref ref-type="bibr" rid="ref-1">1</xref></sup>. The skin manifestations of TSC, including facial angiofibromas, periungual fibromas, hypomelanotic macules formerly known as “ash leaf spots”, and areas of thickened leathery skin (shagreen patches), were recognized clinically long before the pathogenesis was identified. TSC causes multi-system involvement, including benign tumors in the brain, kidneys, heart, eyes, lungs, and skin as well as seizures, intellectual disability, autism spectrum disorders, and other neuropsychiatric disorders. It is inherited in an autosomal dominant pattern, but the rate of spontaneous mutations is high
<sup><xref ref-type="bibr" rid="ref-1">1</xref></sup>. The neurobiology of TSC has been linked to mutations in the
<italic>TSC1</italic> or
<italic>TSC2</italic> genes leading to dysfunction of the TSC1 or TSC2 proteins, which form a complex that usually inhibits mechanistic target of rapamycin (mTOR)
<sup><xref ref-type="bibr" rid="ref-2">2</xref>,
<xref ref-type="bibr" rid="ref-3">3</xref></sup>. These proteins form a complex that integrates the input from upstream cellular pathways, including insulin, growth factors (such as insulin-like growth factor-1 and brain-derived neurotrophic factor), and amino acids. The mTOR pathway is a central regulator of mammalian metabolism and physiology and normally senses cellular nutrient, oxygen, and energy levels
<sup><xref ref-type="bibr" rid="ref-4">4</xref></sup>. Dis-inhibition of this pathway caused by loss-of-function mutations in
<italic>TSC1</italic> or
<italic>TSC2</italic> leads to generally benign overgrowth or tumors in brain, kidney, skin, eye, and other organs that are the clinical hallmarks of the disorder
<sup><xref ref-type="bibr" rid="ref-3">3</xref></sup>. In addition to TSC, alterations in mTOR have been reported in a number of other genetic neurologic disorders, including neurofibromatosis 1, fragile X syndrome, Proteus syndrome, and phosphatase and tensin homolog (PTEN) mutations in Cowden syndrome, Lhermitte-Duclos syndrome, and related disorders
<sup><xref ref-type="bibr" rid="ref-3">3</xref></sup>. PTEN mutation disorders are usually associated with macrocephaly and may be associated with cancer.</p>
<p>A specific combination of major and minor features of TSC is required to make a clinical diagnosis of the disorder (
<xref ref-type="table" rid="T1">Table 1</xref>)
<sup><xref ref-type="bibr" rid="ref-5">5</xref></sup>. An identified genetic mutation in either
<italic>TSC1</italic> or
<italic>TSC2</italic> is also an independent criterion for diagnosis. Epilepsy (90%)
<sup><xref ref-type="bibr" rid="ref-6">6</xref>–
<xref ref-type="bibr" rid="ref-13">13</xref></sup>, intellectual disability (45%)
<sup><xref ref-type="bibr" rid="ref-14">14</xref>–
<xref ref-type="bibr" rid="ref-18">18</xref></sup>, and autism (61%)
<sup><xref ref-type="bibr" rid="ref-19">19</xref>–
<xref ref-type="bibr" rid="ref-33">33</xref></sup> are prominent features of TSC but are relatively non-specific and are not diagnostic. Autism, intellectual disability, and related conditions are classified as TSC-associated neuropsychiatric disorders (TAND)
<sup><xref ref-type="bibr" rid="ref-34">34</xref></sup>.</p>
<table-wrap id="T1" orientation="portrait" position="anchor">
<label>Table 1. </label>
<caption>
<title>Major and minor features required to make a clinical diagnosis of tuberous sclerosis complex.</title>
</caption>
<table content-type="article-table" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Major features</th>
<th align="left" colspan="1" rowspan="1" valign="top">Minor features</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">1. Hypomelanotic macules
<break></break>(≥3 at least 5 mm in diameter)</td>
<td align="left" colspan="1" rowspan="1" valign="top">1. “Confetti” skin lesions</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">2. Angiofibromas (≥3) or fibrous
<break></break>cephalic plaque</td>
<td align="left" colspan="1" rowspan="1" valign="top">2. Dental enamel pits (&gt;3)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">3. Ungual fibromas (≥2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">3. Intraoral fibromas (≥2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">4. Shagreen patch</td>
<td align="left" colspan="1" rowspan="1" valign="top">4. Retinal achromatic patch</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">5. Multiple retinal hamartomas</td>
<td align="left" colspan="1" rowspan="1" valign="top">5. Multiple renal cysts</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">6. Cortical dysplasias
<sup><xref ref-type="other" rid="fn1">a</xref></sup>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">6. Nonrenal hamartomas</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">7. Subependymal nodules</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">8. Subependymal giant cell
<break></break>astrocytoma</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">9. Cardiac rhabdomyoma</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">10. Lymphangioleiomyomatosis
<sup><xref ref-type="other" rid="fn1">b</xref></sup>
</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">11. Angiomyolipomas (&gt;2)
<sup><xref ref-type="other" rid="fn1">b</xref></sup>
</td>
<td colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p id="fn1">
<sup>a</sup>Definite diagnosis: Two major features or one major feature with at least two minor features. Possible diagnosis: Either one major feature or at least two minor features. Cortical dysplasia includes tubers and cerebral white matter radial migration lines.
<sup>b</sup>A combination of the two major clinical features (lymphangioleiomyomatosis and angiomyolipomas) without other features does not meet criteria for a definite diagnosis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Two drugs that inhibit mTOR, sirolimus and everolimus, which were originally developed as immunosuppressive and anti-cancer agents, have recently been applied to treat the manifestations of TSC. These drugs are now US Food and Drug Administration (FDA)-approved for TSC-associated subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomata, and pulmonary lymphangioleiomyomatosis
<sup><xref ref-type="bibr" rid="ref-35">35</xref>–
<xref ref-type="bibr" rid="ref-38">38</xref></sup>. Deficiency of the major inhibitory neurotransmitter amino acid GABA (gamma-aminobutyric acid) has been linked to the high incidence of seizures in TSC
<sup><xref ref-type="bibr" rid="ref-39">39</xref>,
<xref ref-type="bibr" rid="ref-40">40</xref></sup>, and the anticonvulsant drug vigabatrin, an irreversible inhibitor of GABA transaminase, which degrades GABA, has been shown to be effective for treatment of infantile spasms and refractory complex partial seizures associated with TSC
<sup><xref ref-type="bibr" rid="ref-41">41</xref>,
<xref ref-type="bibr" rid="ref-42">42</xref></sup>. European practice guidelines recommend it as a first line for treatment of seizures in infants with TSC
<sup><xref ref-type="bibr" rid="ref-43">43</xref></sup>, and it is considered as neurobiologically targeted treatment for TSC.</p>
<sec>
<title>Treatment of seizures in patients with tuberous sclerosis complex</title>
<p>Several recent studies have reported beneficial effects of everolimus for epilepsy in patients with TSC. Krueger
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-44">44</xref></sup> studied the effect of everolimus in children older than 2 years of age with confirmed TSC and medically refractory epilepsy averaging two or more seizures a week in the months prior to enrollment. These patients failed to respond to trials of two other anticonvulsants. Fourteen of 18 patients who completed the study over 48 months were reported to have a 48% reduction in seizures with few side effects. Samueli
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-45">45</xref></sup> reported on the effect of everolimus in 15 children with TSC less than 18 years of age who had focal seizures, tonic clonic-seizures, or drop attacks (or a combination of these); the authors found that 80% of patients reported fewer seizures and that 58% were seizure-free at a median follow-up of 22 months. French
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-46">46</xref></sup> reported on a placebo controlled trial of 366 patients (age range of 2 to 65 years) who were given everolimus as an add-on therapy for treatment-resistant focal onset seizures associated with TSC (EXIST-3); the authors found response rates of 29% in patients given a low dose, 40% in patients given a higher dose, and 15% in a placebo control group. Adverse drug reactions led to discontinuation of medication in 2%. These trials indicate that mTOR inhibition shows promise for improving seizure control in patients with TSC.</p>
</sec>
<sec>
<title>Spectrum of tuberous sclerosis complex-associated neuropsychiatric disorders</title>
<p>TAND is a term that encompasses the multi-faceted nature of neurodevelopmental disabilities seen in patients with TSC, including behavioral, psychiatric, intellectual, academic, neuropsychological, and psychosocial difficulties
<sup><xref ref-type="bibr" rid="ref-47">47</xref>–
<xref ref-type="bibr" rid="ref-49">49</xref></sup>. Behavioral manifestations may be relatively mild such as poor eye contact or more severe disorders on the autism spectrum, including self-injury (10%) and aggression (45%)
<sup><xref ref-type="bibr" rid="ref-49">49</xref>–
<xref ref-type="bibr" rid="ref-51">51</xref></sup>. Anxiety, depression, attention-deficit/hyperactivity disorder, autism spectrum disorder, and other psychiatric concerns are also common among patients with TSC
<sup><xref ref-type="bibr" rid="ref-13">13</xref>,
<xref ref-type="bibr" rid="ref-52">52</xref>–
<xref ref-type="bibr" rid="ref-55">55</xref></sup>. It is estimated that as many as 50% may be impacted by some level of intellectual disability
<sup><xref ref-type="bibr" rid="ref-13">13</xref>,
<xref ref-type="bibr" rid="ref-52">52</xref>–
<xref ref-type="bibr" rid="ref-56">56</xref></sup>. Academic difficulties in the absence of intellectual disability have also been observed in 30% of individuals with TSC
<sup><xref ref-type="bibr" rid="ref-56">56</xref></sup>. Specific neuropsychological deficits, such as impaired working memory, may also be problematic
<sup><xref ref-type="bibr" rid="ref-55">55</xref></sup>. The concept of TAND also encompasses the psychosocial impact of the individual’s condition on the rest of the family
<sup><xref ref-type="bibr" rid="ref-57">57</xref></sup>. To enable physicians and other medical professionals to screen for these concerns, the TAND checklist has been created
<sup><xref ref-type="bibr" rid="ref-34">34</xref></sup>.</p>
</sec>
<sec>
<title>Treatment of tuberous sclerosis-associated neuropsychiatric disorder</title>
<p>There are no medications approved by the FDA for treatment of TAND, and more progress is needed in this area. Several studies of genetic mouse models of TSC suggest that mTOR inhibitors can reverse deficits in synaptic plasticity, neurobehavior, social impairment, and repetitive behaviors
<sup><xref ref-type="bibr" rid="ref-3">3</xref></sup>. In an open-label phase II trial to evaluate the efficacy and safety of rapamycin in adults with angiomyolipomata and TSC, seven out of eight patients had improvement in neurocognitive deficits, including list learning and story recall
<sup><xref ref-type="bibr" rid="ref-58">58</xref></sup>. Two studies are in progress to address the treatment of TAND
<sup><xref ref-type="bibr" rid="ref-46">46</xref></sup>. The RAD001 Neurocognition Trial (
<ext-link ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov/ct2/show/NCT01289912">www.ClinicalTrials.gov/ct2/show/NCT01289912</ext-link>) is a phase II randomized trial of everolimus in children and young adults ages 6 to 21 years who are being followed with neuropsychological testing. The phase III EXIST-3 trial (NCT01713946) is evaluating the effects of everolimus by using the Vineland Adaptive Behavior Scales, Second Edition
<sup><xref ref-type="bibr" rid="ref-59">59</xref></sup>. In a young man with TSC, a SEGA, epilepsy, aggression, and self-injurious behavior, treatment with everolimus resulted in size reduction of his SEGA, reduction in self-injurious behavior, and diminished seizure frequency
<sup><xref ref-type="bibr" rid="ref-60">60</xref></sup>. Discovering the potential role for neurobiologically targeted medications for behavior in TSC is the basis of our ongoing research program.</p>
</sec>
<sec>
<title>Early treatment of infantile spasms may salvage cognitive development</title>
<p>The inter-relationship between infantile spasms and TAND in tuberous sclerosis is an interesting one that may hold clues to the pathways by which TSC can cause autism and intellectual disabilities. Approximately 30% of patients with TSC present in infancy with infantile spasms, a severe form of epilepsy associated with a hypsarrhthymia pattern on electroencephalography. These patients are at much greater risk for severe autism, intellectual disability, and behavioral disorders compared with TSC patients who do not have infantile spasms. On the other hand, patients with idiopathic infantile spasms are at much lower risk for TAND than are patients with TSC. Early treatment with vigabatrin appears to be protective against severe TAND. For example, one study of infants with TSC compared (a) initiation of treatment with vigabatrin at the onset of electroencephalogram (EEG) abnormalities on anticipatory recordings determined before seizures were witnessed with (b) treatment initiation upon the onset of witnessed seizures
<sup><xref ref-type="bibr" rid="ref-61">61</xref></sup>. No cases of severe/profound intellectual disability were detected among those with the EEG-based treatment
<sup><xref ref-type="bibr" rid="ref-61">61</xref>,
<xref ref-type="bibr" rid="ref-62">62</xref></sup>. A second study, designed to address the question of whether an EEG could be used as a biomarker in infants with TSC, validated its use in this regard
<sup><xref ref-type="bibr" rid="ref-63">63</xref></sup>. Bolton
<italic>et al</italic>.
<sup><xref ref-type="bibr" rid="ref-16">16</xref></sup> reported that
<italic>TSC2</italic> mutations were also associated with significantly higher cortical tuber count than
<italic>TSC1</italic> mutations, and the tuber count was directly related to earlier age and onset of seizures. In turn, the severity of epilepsy was strongly associated with the degree of intellectual impairment. Structural equation modeling, a multivariate statistical analysis technique that combines factor and multiple regression analysis to analyze structural relationships, supported a causal pathway from genetic abnormality to tuber count to epilepsy, including infantile spasms, to severity of intellectual outcome
<sup><xref ref-type="bibr" rid="ref-64">64</xref></sup>. Humphrey
<italic>et al</italic>. reported that there is a dose-dependent impairment of intellectual development following exposure to infantile spasms in children with TSC
<sup><xref ref-type="bibr" rid="ref-64">64</xref></sup>. Recently, it was reported that hormonal therapy with either adrenocorticotropic hormone or prednisolone plus vigabatrin is significantly more effective than hormonal therapy alone at stopping infantile spasms in infants without TSC
<sup><xref ref-type="bibr" rid="ref-65">65</xref>,
<xref ref-type="bibr" rid="ref-66">66</xref></sup>. Therefore, evaluating combination therapy could be useful in patients with TSC and spasms as early termination of spasms is critically important to prevent additional injury.</p>
</sec>
<sec>
<title>Summary</title>
<p>Tuberous sclerosis is a genetic multi-system disease that can have a major impact on the developing brain to cause seizures and an array of severe neuropsychiatric disorders, including severe intellectual disability and autism spectrum disorders. Recognition of the role of mutations in the
<italic>TSC1</italic> and
<italic>TSC2</italic> genes and the mTOR signaling pathways has led to the use of mTOR inhibitors to arrest or lessen the impact of the disorder. These medications have had a major impact in the brain and may also have an anti-epileptic effect. The concept of TAND has led to greater recognition of a host of disorders that can cause a great deal of impairment. The development of a common terminology for TAND to address the varying levels of involvement and the creation of the TAND checklist to aid clinicians and researchers in screening for these concerns provide a foundation for uniformity. Recognition that early onset of seizures, especially infantile spasms, are common in infants with TSC and that early onset of infantile spasms and associated hypsarrhythmia may have a malignant effect on brain development in infants with TSC has stimulated the search for ways to anticipate the onset of infantile spasms before they become apparent as seizures. Recent data suggesting that hormonal therapy combined with vigabatrin may stop spasms more quickly may have important benefits for patients with TSC. This information, combined with an understanding of the genetics and neurobiology of TSC, is leading to a deeper understanding of pathogenesis and possibly better therapies.</p>
</sec>
</body>
<back>
<ref-list>
<ref id="ref-1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caban</surname><given-names>C</given-names></name><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>Hasbani</surname><given-names>DM</given-names></name><etal></etal></person-group>:
<article-title>Genetics of tuberous sclerosis complex: implications for clinical practice.</article-title>
<source/><italic>Appl Clin Genet.</italic>
<year>2016</year>;<volume>10</volume>:<fpage>1</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.2147/TACG.S90262</pub-id>
<!--<pub-id pub-id-type="pmcid">5189696</pub-id>-->
<pub-id pub-id-type="pmid">28053551</pub-id></mixed-citation>
</ref>
<ref id="ref-2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoeffer</surname><given-names>CA</given-names></name><name><surname>Klann</surname><given-names>E</given-names></name></person-group>:
<article-title>mTOR signaling: at the crossroads of plasticity, memory and disease.</article-title>
<source/><italic>Trends Neurosci.</italic>
<year>2010</year>;<volume>33</volume>(<issue>2</issue>):<fpage>67</fpage>–<lpage>75</lpage>.
<pub-id pub-id-type="doi">10.1016/j.tins.2009.11.003</pub-id>
<!--<pub-id pub-id-type="pmcid">2821969</pub-id>-->
<pub-id pub-id-type="pmid">19963289</pub-id></mixed-citation>
</ref>
<ref id="ref-3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Switon</surname><given-names>K</given-names></name><name><surname>Kotulska</surname><given-names>K</given-names></name><name><surname>Janusz-Kaminska</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Molecular neurobiology of mTOR.</article-title>
<source/><italic>Neuroscience.</italic>
<year>2017</year>;<volume>341</volume>:<fpage>112</fpage>–<lpage>53</lpage>.
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.11.017</pub-id>
<pub-id pub-id-type="pmid">27889578</pub-id></mixed-citation>
</ref>
<ref id="ref-4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crino</surname><given-names>PB</given-names></name></person-group>:
<article-title>The mTOR signalling cascade: paving new roads to cure neurological disease.</article-title>
<source/><italic>Nat Rev Neurol.</italic>
<year>2016</year>;<volume>12</volume>(<issue>7</issue>):<fpage>379</fpage>–<lpage>92</lpage>.
<pub-id pub-id-type="doi">10.1038/nrneurol.2016.81</pub-id>
<pub-id pub-id-type="pmid">27340022</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726447263">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Northrup</surname><given-names>H</given-names></name><name><surname>Krueger</surname><given-names>DA</given-names></name></person-group>,
<collab>International Tuberous Sclerosis Complex Consensus Group: </collab>
<article-title>Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.</article-title>
<source/><italic>Pediatr Neurol.</italic>
<year>2013</year>;<volume>49</volume>(<issue>4</issue>):<fpage>243</fpage>–<lpage>54</lpage>.
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2013.08.001</pub-id>
<!--<pub-id pub-id-type="pmcid">4080684</pub-id>-->
<pub-id pub-id-type="pmid">24053982</pub-id></mixed-citation>
</ref>
<ref id="ref-6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cross</surname><given-names>JH</given-names></name></person-group>:
<article-title>Neurocutaneous syndromes and epilepsy-issues in diagnosis and management.</article-title>
<source/><italic>Epilepsia.</italic>
<year>2005</year>;<volume>46 Suppl 10</volume>:<fpage>17</fpage>–<lpage>23</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2005.00353.x</pub-id>
<pub-id pub-id-type="pmid">16359466</pub-id></mixed-citation>
</ref>
<ref id="ref-7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curatolo</surname><given-names>P</given-names></name><name><surname>Bombardieri</surname><given-names>R</given-names></name><name><surname>Verdecchia</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment.</article-title>
<source/><italic>J Child Neurol.</italic>
<year>2005</year>;<volume>20</volume>(<issue>4</issue>):<fpage>318</fpage>–<lpage>25</lpage>.
<pub-id pub-id-type="doi">10.1177/08830738050200040901</pub-id>
<pub-id pub-id-type="pmid">15921233</pub-id></mixed-citation>
</ref>
<ref id="ref-8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riikonen</surname><given-names>R</given-names></name><name><surname>Simell</surname><given-names>O</given-names></name></person-group>:
<article-title>Tuberous sclerosis and infantile spasms.</article-title>
<source/><italic>Dev Med Child Neurol.</italic>
<year>1990</year>;<volume>32</volume>(<issue>3</issue>):<fpage>203</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1469-8749.1990.tb16926.x</pub-id>
<pub-id pub-id-type="pmid">2155840</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/721643799">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>CW</given-names></name><name><surname>Stephenson</surname><given-names>JB</given-names></name></person-group>:
<article-title>Seizures and intellectual disability associated with tuberous sclerosis complex in the west of Scotland.</article-title>
<source/><italic>Dev Med Child Neurol.</italic>
<year>1992</year>;<volume>34</volume>(<issue>9</issue>):<fpage>766</fpage>–<lpage>74</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1469-8749.1992.tb11515.x</pub-id>
<pub-id pub-id-type="pmid">1526347</pub-id></mixed-citation>
</ref>
<ref id="ref-10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chu-Shore</surname><given-names>CJ</given-names></name><name><surname>Major</surname><given-names>P</given-names></name><name><surname>Camposano</surname><given-names>S</given-names></name><etal></etal></person-group>:
<article-title>The natural history of epilepsy in tuberous sclerosis complex.</article-title>
<source/><italic>Epilepsia.</italic>
<year>2010</year>;<volume>51</volume>(<issue>7</issue>):<fpage>1236</fpage>–<lpage>41</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2009.02474.x</pub-id>
<!--<pub-id pub-id-type="pmcid">3065368</pub-id>-->
<pub-id pub-id-type="pmid">20041940</pub-id></mixed-citation>
</ref>
<ref id="ref-11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dombkowski</surname><given-names>AA</given-names></name><name><surname>Batista</surname><given-names>CE</given-names></name><name><surname>Cukovic</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>Cortical Tubers: Windows into Dysregulation of Epilepsy Risk and Synaptic Signaling Genes by MicroRNAs.</article-title>
<source/><italic>Cereb Cortex.</italic>
<year>2016</year>;<volume>26</volume>(<issue>3</issue>):<fpage>1059</fpage>–<lpage>71</lpage>.
<pub-id pub-id-type="doi">10.1093/cercor/bhu276</pub-id>
<!--<pub-id pub-id-type="pmcid">4737604</pub-id>-->
<pub-id pub-id-type="pmid">25452577</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725259718">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hunt</surname><given-names>A</given-names></name></person-group>:
<article-title>Development, behaviour and seizures in 300 cases of tuberous sclerosis.</article-title>
<source/><italic>J Intellect Disabil Res.</italic>
<year>1993</year>;<volume>37</volume>(<issue>Pt 1</issue>):<fpage>41</fpage>–<lpage>51</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1365-2788.1993.tb00868.x</pub-id>
<pub-id pub-id-type="pmid">7681710</pub-id></mixed-citation>
</ref>
<ref id="ref-13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Joinson</surname><given-names>C</given-names></name><name><surname>O'Callaghan</surname><given-names>FJ</given-names></name><name><surname>Osborne</surname><given-names>JP</given-names></name><etal></etal></person-group>:
<article-title>Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex.</article-title>
<source/><italic>Psychol Med.</italic>
<year>2003</year>;<volume>33</volume>(<issue>2</issue>):<fpage>335</fpage>–<lpage>44</lpage>.
<pub-id pub-id-type="doi">10.1017/S0033291702007092</pub-id>
<pub-id pub-id-type="pmid">12622312</pub-id></mixed-citation>
</ref>
<ref id="ref-14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jansen</surname><given-names>FE</given-names></name><name><surname>Vincken</surname><given-names>KL</given-names></name><name><surname>Algra</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Cognitive impairment in tuberous sclerosis complex is a multifactorial condition.</article-title>
<source/><italic>Neurology.</italic>
<year>2008</year>;<volume>70</volume>(<issue>12</issue>):<fpage>916</fpage>–<lpage>23</lpage>.
<pub-id pub-id-type="doi">10.1212/01.wnl.0000280579.04974.c0</pub-id>
<pub-id pub-id-type="pmid">18032744</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/1098010">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaczorowska</surname><given-names>M</given-names></name><name><surname>Jurkiewicz</surname><given-names>E</given-names></name><name><surname>Domanska-Pakiela</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>Cerebral tuber count and its impact on mental outcome of patients with tuberous sclerosis complex.</article-title>
<source/><italic>Epilepsia.</italic>
<year>2011</year>;<volume>52</volume>(<issue>1</issue>):<fpage>22</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02892.x</pub-id>
<pub-id pub-id-type="pmid">21204819</pub-id></mixed-citation>
</ref>
<ref id="ref-16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bolton</surname><given-names>PF</given-names></name><name><surname>Clifford</surname><given-names>M</given-names></name><name><surname>Tye</surname><given-names>C</given-names></name><etal></etal></person-group>:
<article-title>Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the Tuberous Sclerosis 2000 Study.</article-title>
<source/><italic>Psychol Med.</italic>
<year>2015</year>;<volume>45</volume>(<issue>11</issue>):<fpage>2321</fpage>–<lpage>31</lpage>.
<pub-id pub-id-type="doi">10.1017/S0033291715000264</pub-id>
<pub-id pub-id-type="pmid">25827976</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725415302">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>HT</given-names></name><name><surname>McCartney</surname><given-names>DL</given-names></name><name><surname>Lewis</surname><given-names>JC</given-names></name><etal></etal></person-group>:
<article-title>Intellectual ability in tuberous sclerosis complex correlates with predicted effects of mutations on TSC1 and TSC2 proteins.</article-title>
<source/><italic>J Med Genet.</italic>
<year>2015</year>;<volume>52</volume>(<issue>12</issue>):<fpage>815</fpage>–<lpage>22</lpage>.
<pub-id pub-id-type="doi">10.1136/jmedgenet-2015-103154</pub-id>
<pub-id pub-id-type="pmid">26408672</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727603294">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Overwater</surname><given-names>IE</given-names></name><name><surname>Verhaar</surname><given-names>BJ</given-names></name><name><surname>Lingsma</surname><given-names>HF</given-names></name><etal></etal></person-group>:
<article-title>Interdependence of clinical factors predicting cognition in children with tuberous sclerosis complex.</article-title>
<source/><italic>J Neurol.</italic>
<year>2017</year>;<volume>264</volume>(<issue>1</issue>):<fpage>161</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1007/s00415-016-8335-5</pub-id>
<!--<pub-id pub-id-type="pmcid">5225189</pub-id>-->
<pub-id pub-id-type="pmid">27878438</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727013446">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gipson</surname><given-names>TT</given-names></name><name><surname>Poretti</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>EA</given-names></name><etal></etal></person-group>:
<article-title>Autism Phenotypes in Tuberous Sclerosis Complex: Diagnostic and Treatment Considerations.</article-title>
<source/><italic>J Child Neurol.</italic>
<year>2015</year>;<volume>30</volume>(<issue>14</issue>):<fpage>1871</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1177/0883073815600871</pub-id>
<pub-id pub-id-type="pmid">26303410</pub-id></mixed-citation>
</ref>
<ref id="ref-20">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vignoli</surname><given-names>A</given-names></name><name><surname>La Briola</surname><given-names>F</given-names></name><name><surname>Peron</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Autism spectrum disorder in tuberous sclerosis complex: searching for risk markers.</article-title>
<source/><italic>Orphanet J Rare Dis.</italic>
<year>2015</year>;<volume>10</volume>:<fpage>154</fpage>.
<pub-id pub-id-type="doi">10.1186/s13023-015-0371-1</pub-id>
<!--<pub-id pub-id-type="pmcid">4668631</pub-id>-->
<pub-id pub-id-type="pmid">26631248</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725982934">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jeste</surname><given-names>SS</given-names></name><name><surname>Varcin</surname><given-names>KJ</given-names></name><name><surname>Hellemann</surname><given-names>GS</given-names></name><etal></etal></person-group>:
<article-title>Symptom profiles of autism spectrum disorder in tuberous sclerosis complex.</article-title>
<source/><italic>Neurology.</italic>
<year>2016</year>;<volume>87</volume>(<issue>8</issue>):<fpage>766</fpage>–<lpage>72</lpage>.
<pub-id pub-id-type="doi">10.1212/WNL.0000000000003002</pub-id>
<!--<pub-id pub-id-type="pmcid">4999317</pub-id>-->
<pub-id pub-id-type="pmid">27440144</pub-id></mixed-citation>
</ref>
<ref id="ref-22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hampson</surname><given-names>DR</given-names></name><name><surname>Blatt</surname><given-names>GJ</given-names></name></person-group>:
<article-title>Autism spectrum disorders and neuropathology of the cerebellum.</article-title>
<source/><italic>Front Neurosci.</italic>
<year>2015</year>;<volume>9</volume>:<fpage>420</fpage>.
<pub-id pub-id-type="doi">10.3389/fnins.2015.00420</pub-id>
<!--<pub-id pub-id-type="pmcid">4635214</pub-id>-->
<pub-id pub-id-type="pmid">26594141</pub-id></mixed-citation>
</ref>
<ref id="ref-23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gillberg</surname><given-names>IC</given-names></name><name><surname>Gillberg</surname><given-names>C</given-names></name><name><surname>Ahlsen</surname><given-names>G</given-names></name></person-group>:
<article-title>Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study.</article-title>
<source/><italic>Dev Med Child Neurol.</italic>
<year>1994</year>;<volume>36</volume>(<issue>1</issue>):<fpage>50</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1469-8749.1994.tb11765.x</pub-id>
<pub-id pub-id-type="pmid">8132114</pub-id></mixed-citation>
</ref>
<ref id="ref-24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hunt</surname><given-names>A</given-names></name><name><surname>Shepherd</surname><given-names>C</given-names></name></person-group>:
<article-title>A prevalence study of autism in tuberous sclerosis.</article-title>
<source/><italic>J Autism Dev Disord.</italic>
<year>1993</year>;<volume>23</volume>(<issue>2</issue>):<fpage>323</fpage>–<lpage>39</lpage>.
<pub-id pub-id-type="doi">10.1007/BF01046223</pub-id>
<pub-id pub-id-type="pmid">8331050</pub-id></mixed-citation>
</ref>
<ref id="ref-25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jambaqué</surname><given-names>I</given-names></name><name><surname>Cusmai</surname><given-names>R</given-names></name><name><surname>Curatolo</surname><given-names>P</given-names></name><etal></etal></person-group>:
<article-title>Neuropsychological aspects of tuberous sclerosis in relation to epilepsy and MRI findings.</article-title>
<source/><italic>Dev Med Child Neurol.</italic>
<year>1991</year>;<volume>33</volume>(<issue>8</issue>):<fpage>698</fpage>–<lpage>705</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1469-8749.1991.tb14947.x</pub-id>
<pub-id pub-id-type="pmid">1916024</pub-id></mixed-citation>
</ref>
<ref id="ref-26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smalley</surname><given-names>SL</given-names></name><name><surname>Tanguay</surname><given-names>PE</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Autism and tuberous sclerosis.</article-title>
<source/><italic>J Autism Dev Disord.</italic>
<year>1992</year>;<volume>22</volume>(<issue>3</issue>):<fpage>339</fpage>–<lpage>55</lpage>.
<pub-id pub-id-type="doi">10.1007/bf01048239</pub-id>
<pub-id pub-id-type="pmid">1400103</pub-id></mixed-citation>
</ref>
<ref id="ref-27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baker</surname><given-names>P</given-names></name><name><surname>Piven</surname><given-names>J</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name></person-group>:
<article-title>Autism and tuberous sclerosis complex: prevalence and clinical features.</article-title>
<source/><italic>J Autism Dev Disord.</italic>
<year>1998</year>;<volume>28</volume>(<issue>4</issue>):<fpage>279</fpage>–<lpage>85</lpage>.
<pub-id pub-id-type="doi">10.1023/A:1026004501631</pub-id>
<pub-id pub-id-type="pmid">9711484</pub-id></mixed-citation>
</ref>
<ref id="ref-28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gutierrez</surname><given-names>GC</given-names></name><name><surname>Smalley</surname><given-names>SL</given-names></name><name><surname>Tanguay</surname><given-names>PE</given-names></name></person-group>:
<article-title>Autism in tuberous sclerosis complex.</article-title>
<source/><italic>J Autism Dev Disord.</italic>
<year>1998</year>;<volume>28</volume>(<issue>2</issue>):<fpage>97</fpage>–<lpage>103</lpage>.
<pub-id pub-id-type="doi">10.1023/A:1026032413811</pub-id>
<pub-id pub-id-type="pmid">9586771</pub-id></mixed-citation>
</ref>
<ref id="ref-29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jeste</surname><given-names>SS</given-names></name><name><surname>Sahin</surname><given-names>M</given-names></name><name><surname>Bolton</surname><given-names>P</given-names></name><etal></etal></person-group>:
<article-title>Characterization of autism in young children with tuberous sclerosis complex.</article-title>
<source/><italic>J Child Neurol.</italic>
<year>2008</year>;<volume>23</volume>(<issue>5</issue>):<fpage>520</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1177/0883073807309788</pub-id>
<pub-id pub-id-type="pmid">18160549</pub-id></mixed-citation>
</ref>
<ref id="ref-30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Calderón González</surname><given-names>R</given-names></name><name><surname>Treviño Welsh</surname><given-names>J</given-names></name><name><surname>Calderón Sepúlveda</surname><given-names>A</given-names></name></person-group>:
<article-title>[Autism in tuberous sclerosis].</article-title>
<source/><italic>Gac Med Mex.</italic>
<year>1994</year>;<volume>130</volume>(<issue>5</issue>):<fpage>374</fpage>–<lpage>379</lpage>.
<pub-id pub-id-type="pmid">7607368</pub-id></mixed-citation>
</ref>
<ref id="ref-31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Numis</surname><given-names>AL</given-names></name><name><surname>Major</surname><given-names>P</given-names></name><name><surname>Montenegro</surname><given-names>MA</given-names></name><etal></etal></person-group>:
<article-title>Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex.</article-title>
<source/><italic>Neurology.</italic>
<year>2011</year>;<volume>76</volume>(<issue>11</issue>):<fpage>981</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1212/WNL.0b013e3182104347</pub-id>
<!--<pub-id pub-id-type="pmcid">3271577</pub-id>-->
<pub-id pub-id-type="pmid">21403110</pub-id></mixed-citation>
</ref>
<ref id="ref-32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bolton</surname><given-names>PF</given-names></name><name><surname>Griffiths</surname><given-names>PD</given-names></name></person-group>:
<article-title>Association of tuberous sclerosis of temporal lobes with autism and atypical autism.</article-title>
<source/><italic>Lancet.</italic>
<year>1997</year>;<volume>349</volume>(<issue>9049</issue>):<fpage>392</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(97)80012-8</pub-id>
<pub-id pub-id-type="pmid">9033466</pub-id></mixed-citation>
</ref>
<ref id="ref-33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Granader</surname><given-names>YE</given-names></name><name><surname>Bender</surname><given-names>HA</given-names></name><name><surname>Zemon</surname><given-names>V</given-names></name><etal></etal></person-group>:
<article-title>The clinical utility of the Social Responsiveness Scale and Social Communication Questionnaire in tuberous sclerosis complex.</article-title>
<source/><italic>Epilepsy Behav.</italic>
<year>2010</year>;<volume>18</volume>(<issue>3</issue>):<fpage>262</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1016/j.yebeh.2010.04.010</pub-id>
<pub-id pub-id-type="pmid">20554253</pub-id></mixed-citation>
</ref>
<ref id="ref-34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Vries</surname><given-names>PJ</given-names></name><name><surname>Whittemore</surname><given-names>VH</given-names></name><name><surname>Leclezio</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist.</article-title>
<source/><italic>Pediatr Neurol.</italic>
<year>2015</year>;<volume>52</volume>(<issue>1</issue>):<fpage>25</fpage>–<lpage>35</lpage>.
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2014.10.004</pub-id>
<!--<pub-id pub-id-type="pmcid">4427347</pub-id>-->
<pub-id pub-id-type="pmid">25532776</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/725295188">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Franz</surname><given-names>DN</given-names></name></person-group>:
<article-title>Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.</article-title>
<source/><italic>Expert Rev Anticancer Ther.</italic>
<year>2011</year>;<volume>11</volume>(<issue>8</issue>):<fpage>1181</fpage>–<lpage>92</lpage>.
<pub-id pub-id-type="doi">10.1586/era.11.93</pub-id>
<pub-id pub-id-type="pmid">21916571</pub-id></mixed-citation>
</ref>
<ref id="ref-36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curran</surname><given-names>MP</given-names></name></person-group>:
<article-title>Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.</article-title>
<source/><italic>Paediatr Drugs.</italic>
<year>2012</year>;<volume>14</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>60</lpage>.
<pub-id pub-id-type="doi">10.2165/11207730-000000000-00000</pub-id>
<pub-id pub-id-type="pmid">22136276</pub-id></mixed-citation>
</ref>
<ref id="ref-37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bissler</surname><given-names>JJ</given-names></name><name><surname>Kingswood</surname><given-names>JC</given-names></name><name><surname>Radzikowska</surname><given-names>E</given-names></name><etal></etal></person-group>:
<article-title>Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.</article-title>
<source/><italic>Lancet.</italic>
<year>2013</year>;<volume>381</volume>(<issue>9869</issue>):<fpage>817</fpage>–<lpage>24</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(12)61767-X</pub-id>
<pub-id pub-id-type="pmid">23312829</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/717976446">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCormack</surname><given-names>FX</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Moss</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Efficacy and safety of sirolimus in lymphangioleiomyomatosis.</article-title>
<source/><italic>N Engl J Med.</italic>
<year>2011</year>;<volume>364</volume>(<issue>17</issue>):<fpage>1595</fpage>–<lpage>606</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMoa1100391</pub-id>
<!--<pub-id pub-id-type="pmcid">3118601</pub-id>-->
<pub-id pub-id-type="pmid">21410393</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/9404956">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Talos</surname><given-names>DM</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Kosaras</surname><given-names>B</given-names></name><etal></etal></person-group>:
<article-title>Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia.</article-title>
<source/><italic>Ann Neurol.</italic>
<year>2012</year>;<volume>71</volume>(<issue>4</issue>):<fpage>539</fpage>–<lpage>51</lpage>.
<pub-id pub-id-type="doi">10.1002/ana.22696</pub-id>
<!--<pub-id pub-id-type="pmcid">3334406</pub-id>-->
<pub-id pub-id-type="pmid">22447678</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/722951255">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>McDaniel</surname><given-names>SS</given-names></name><name><surname>Rensing</surname><given-names>NR</given-names></name><etal></etal></person-group>:
<article-title>Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.</article-title>
<source/><italic>PLoS One.</italic>
<year>2013</year>;<volume>8</volume>(<issue>2</issue>):<fpage>e57445</fpage>.
<pub-id pub-id-type="doi">10.1371/journal.pone.0057445</pub-id>
<!--<pub-id pub-id-type="pmcid">3577710</pub-id>-->
<pub-id pub-id-type="pmid">23437388</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/717980477">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vigevano</surname><given-names>F</given-names></name><name><surname>Cilio</surname><given-names>MR</given-names></name></person-group>:
<article-title>Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study.</article-title>
<source/><italic>Epilepsia.</italic>
<year>1997</year>;<volume>38</volume>(<issue>12</issue>):<fpage>1270</fpage>–<lpage>4</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1528-1157.1997.tb00063.x</pub-id>
<pub-id pub-id-type="pmid">9578521</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/720656551">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krauss</surname><given-names>G</given-names></name><name><surname>Faught</surname><given-names>E</given-names></name><name><surname>Foroozan</surname><given-names>R</given-names></name><etal></etal></person-group>:
<article-title>Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin.</article-title>
<source/><italic>Epilepsy Behav.</italic>
<year>2016</year>;<volume>56</volume>:<fpage>15</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1016/j.yebeh.2015.12.004</pub-id>
<pub-id pub-id-type="pmid">26807550</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726100831">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wheless</surname><given-names>JW</given-names></name><name><surname>Clarke</surname><given-names>DF</given-names></name><name><surname>Arzimanoglou</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Treatment of pediatric epilepsy: European expert opinion, 2007.</article-title>
<source/><italic>Epileptic Disord.</italic>
<year>2007</year>;<volume>9</volume>(<issue>4</issue>):<fpage>353</fpage>–<lpage>412</lpage>.
<pub-id pub-id-type="pmid">18077226</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727445745">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krueger</surname><given-names>DA</given-names></name><name><surname>Wilfong</surname><given-names>AA</given-names></name><name><surname>Mays</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Long-term treatment of epilepsy with everolimus in tuberous sclerosis.</article-title>
<source/><italic>Neurology.</italic>
<year>2016</year>;<volume>87</volume>(<issue>23</issue>):<fpage>2408</fpage>–<lpage>15</lpage>.
<pub-id pub-id-type="doi">10.1212/WNL.0000000000003400</pub-id>
<!--<pub-id pub-id-type="pmcid">5177677</pub-id>-->
<pub-id pub-id-type="pmid">27815402</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726930267">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Samueli</surname><given-names>S</given-names></name><name><surname>Abraham</surname><given-names>K</given-names></name><name><surname>Dressler</surname><given-names>A</given-names></name><etal></etal></person-group>:
<article-title>Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study.</article-title>
<source/><italic>Orphanet J Rare Dis.</italic>
<year>2016</year>;<volume>11</volume>(<issue>1</issue>):<fpage>145</fpage>.
<pub-id pub-id-type="doi">10.1186/s13023-016-0530-z</pub-id>
<!--<pub-id pub-id-type="pmcid">5094073</pub-id>-->
<pub-id pub-id-type="pmid">27809914</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726924617">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>French</surname><given-names>JA</given-names></name><name><surname>Lawson</surname><given-names>JA</given-names></name><name><surname>Yapici</surname><given-names>Z</given-names></name><etal></etal></person-group>:
<article-title>Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.</article-title>
<source/><italic>Lancet.</italic>
<year>2016</year>;<volume>388</volume>(<issue>10056</issue>):<fpage>2153</fpage>–<lpage>63</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(16)31419-2</pub-id>
<pub-id pub-id-type="pmid">27613521</pub-id></mixed-citation>
</ref>
<ref id="ref-47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Vries</surname><given-names>PJ</given-names></name><name><surname>Hunt</surname><given-names>A</given-names></name><name><surname>Bolton</surname><given-names>PF</given-names></name></person-group>:
<article-title>The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families.</article-title>
<source/><italic>Eur Child Adolesc Psychiatry.</italic>
<year>2007</year>;<volume>16</volume>(<issue>1</issue>):<fpage>16</fpage>–<lpage>24</lpage>.
<pub-id pub-id-type="doi">10.1007/s00787-006-0570-3</pub-id>
<pub-id pub-id-type="pmid">17268883</pub-id></mixed-citation>
</ref>
<ref id="ref-48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curatolo</surname><given-names>P</given-names></name><name><surname>Moavero</surname><given-names>R</given-names></name><name><surname>de Vries</surname><given-names>PJ</given-names></name></person-group>:
<article-title>Neurological and neuropsychiatric aspects of tuberous sclerosis complex.</article-title>
<source/><italic>Lancet Neurol.</italic>
<year>2015</year>;<volume>14</volume>(<issue>7</issue>):<fpage>733</fpage>–<lpage>45</lpage>.
<pub-id pub-id-type="doi">10.1016/S1474-4422(15)00069-1</pub-id>
<pub-id pub-id-type="pmid">26067126</pub-id></mixed-citation>
</ref>
<ref id="ref-49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curatolo</surname><given-names>P</given-names></name><name><surname>Napolioni</surname><given-names>V</given-names></name><name><surname>Moavero</surname><given-names>R</given-names></name></person-group>:
<article-title>Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment.</article-title>
<source/><italic>J Child Neurol.</italic>
<year>2010</year>;<volume>25</volume>(<issue>7</issue>):<fpage>873</fpage>–<lpage>80</lpage>.
<pub-id pub-id-type="doi">10.1177/0883073810361789</pub-id>
<pub-id pub-id-type="pmid">20207609</pub-id></mixed-citation>
</ref>
<ref id="ref-50">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eden</surname><given-names>KE</given-names></name><name><surname>de Vries</surname><given-names>PJ</given-names></name><name><surname>Moss</surname><given-names>J</given-names></name><etal></etal></person-group>:
<article-title>Self-injury and aggression in tuberous sclerosis complex: cross syndrome comparison and associated risk markers.</article-title>
<source/><italic>J Neurodev Disord.</italic>
<year>2014</year>;<volume>6</volume>(<issue>1</issue>):<fpage>10</fpage>.
<pub-id pub-id-type="doi">10.1186/1866-1955-6-10</pub-id>
<!--<pub-id pub-id-type="pmcid">4017702</pub-id>-->
<pub-id pub-id-type="pmid">24822087</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727529799">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bolton</surname><given-names>PF</given-names></name><name><surname>Park</surname><given-names>RJ</given-names></name><name><surname>Higgins</surname><given-names>JN</given-names></name><etal></etal></person-group>:
<article-title>Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex.</article-title>
<source/><italic>Brain.</italic>
<year>2002</year>;<volume>125</volume>(<issue>Pt 6</issue>):<fpage>1247</fpage>–<lpage>55</lpage>.
<pub-id pub-id-type="doi">10.1093/brain/awf124</pub-id>
<pub-id pub-id-type="pmid">12023313</pub-id></mixed-citation>
</ref>
<ref id="ref-52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>JC</given-names></name><name><surname>Thomas</surname><given-names>HV</given-names></name><name><surname>Murphy</surname><given-names>KC</given-names></name><etal></etal></person-group>:
<article-title>Genotype and psychological phenotype in tuberous sclerosis.</article-title>
<source/><italic>J Med Genet.</italic>
<year>2004</year>;<volume>41</volume>(<issue>3</issue>):<fpage>203</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1136/jmg.2003.012757</pub-id>
<!--<pub-id pub-id-type="pmcid">1735680</pub-id>-->
<pub-id pub-id-type="pmid">14985384</pub-id></mixed-citation>
</ref>
<ref id="ref-53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raznahan</surname><given-names>A</given-names></name><name><surname>Joinson</surname><given-names>C</given-names></name><name><surname>O'Callaghan</surname><given-names>F</given-names></name><etal></etal></person-group>:
<article-title>Psychopathology in tuberous sclerosis: an overview and findings in a population-based sample of adults with tuberous sclerosis.</article-title>
<source/><italic>J Intellect Disabil Res.</italic>
<year>2006</year>;<volume>50</volume>(<issue>Pt 8</issue>):<fpage>561</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1365-2788.2006.00828.x</pub-id>
<pub-id pub-id-type="pmid">16867063</pub-id></mixed-citation>
</ref>
<ref id="ref-54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muzykewicz</surname><given-names>DA</given-names></name><name><surname>Newberry</surname><given-names>P</given-names></name><name><surname>Danforth</surname><given-names>N</given-names></name><etal></etal></person-group>:
<article-title>Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex.</article-title>
<source/><italic>Epilepsy Behav.</italic>
<year>2007</year>;<volume>11</volume>(<issue>4</issue>):<fpage>506</fpage>–<lpage>13</lpage>.
<pub-id pub-id-type="doi">10.1016/j.yebeh.2007.07.010</pub-id>
<pub-id pub-id-type="pmid">17936687</pub-id></mixed-citation>
</ref>
<ref id="ref-55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ridler</surname><given-names>K</given-names></name><name><surname>Suckling</surname><given-names>J</given-names></name><name><surname>Higgins</surname><given-names>NJ</given-names></name><etal></etal></person-group>:
<article-title>Neuroanatomical correlates of memory deficits in tuberous sclerosis complex.</article-title>
<source/><italic>Cereb Cortex.</italic>
<year>2007</year>;<volume>17</volume>(<issue>2</issue>):<fpage>261</fpage>–<lpage>71</lpage>.
<pub-id pub-id-type="doi">10.1093/cercor/bhj144</pub-id>
<pub-id pub-id-type="pmid">16603714</pub-id></mixed-citation>
</ref>
<ref id="ref-56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Vries</surname><given-names>PJ</given-names></name><name><surname>Gardiner</surname><given-names>J</given-names></name><name><surname>Bolton</surname><given-names>PF</given-names></name></person-group>:
<article-title>Neuropsychological attention deficits in tuberous sclerosis complex (TSC).</article-title>
<source/><italic>Am J Med Genet A.</italic>
<year>2009</year>;<volume>149A</volume>(<issue>3</issue>):<fpage>387</fpage>–<lpage>95</lpage>.
<pub-id pub-id-type="doi">10.1002/ajmg.a.32690</pub-id>
<pub-id pub-id-type="pmid">19215038</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727603296">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whittemore</surname><given-names>VH</given-names></name><name><surname>Lewis</surname><given-names>J</given-names></name></person-group>:
<article-title>Impact of TSC on the family and genetic counseling issues.</article-title>In: Kwiatkowski DJ, Whittemore VH, Thiele EA, eds.
<italic>Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics.</italic>Weinheim, Germany: Wiley-Blackwell,<year>2010</year>;<fpage>387</fpage>–<lpage>396</lpage>.
<pub-id pub-id-type="doi">10.1002/9783527630073.ch19</pub-id>
</mixed-citation>
</ref>
<ref id="ref-58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davies</surname><given-names>DM</given-names></name><name><surname>de Vries</surname><given-names>PJ</given-names></name><name><surname>Johnson</surname><given-names>SR</given-names></name><etal></etal></person-group>:
<article-title>Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.</article-title>
<source/><italic>Clin Cancer Res.</italic>
<year>2011</year>;<volume>17</volume>(<issue>12</issue>):<fpage>4071</fpage>–<lpage>81</lpage>.
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-0445</pub-id>
<pub-id pub-id-type="pmid">21525172</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/11911959">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Capal</surname><given-names>JK</given-names></name><name><surname>Franz</surname><given-names>DN</given-names></name></person-group>:
<article-title>Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy.</article-title>
<source/><italic>Neuropsychiatr Dis Treat.</italic>
<year>2016</year>;<volume>12</volume>:<fpage>2165</fpage>–<lpage>72</lpage>.
<pub-id pub-id-type="doi">10.2147/NDT.S91248</pub-id>
<!--<pub-id pub-id-type="pmcid">5003595</pub-id>-->
<pub-id pub-id-type="pmid">27601910</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727172710">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gipson</surname><given-names>TT</given-names></name><name><surname>Jennett</surname><given-names>H</given-names></name><name><surname>Wachtel</surname><given-names>L</given-names></name><etal></etal></person-group>:
<article-title>Everolimus and intensive behavioral therapy in an adolescent with tuberous sclerosis complex and severe behavior.</article-title>
<source/><italic>Epilepsy Behav Case Rep.</italic>
<year>2013</year>;<volume>1</volume>:<fpage>122</fpage>–<lpage>5</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ebcr.2013.06.004</pub-id>
<!--<pub-id pub-id-type="pmcid">4150649</pub-id>-->
<pub-id pub-id-type="pmid">25667844</pub-id></mixed-citation>
</ref>
<ref id="ref-61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jóźwiak</surname><given-names>S</given-names></name><name><surname>Kotulska</surname><given-names>K</given-names></name><name><surname>Domańska-Pakieła</surname><given-names>D</given-names></name><etal></etal></person-group>:
<article-title>Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex.</article-title>
<source/><italic>Eur J Paediatr Neurol.</italic>
<year>2011</year>;<volume>15</volume>(<issue>5</issue>):<fpage>424</fpage>–<lpage>31</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ejpn.2011.03.010</pub-id>
<pub-id pub-id-type="pmid">21507691</pub-id></mixed-citation>
</ref>
<ref id="ref-62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Józwiak</surname><given-names>S</given-names></name><name><surname>Domańska-Pakieła</surname><given-names>D</given-names></name><name><surname>Kotulska</surname><given-names>K</given-names></name><etal></etal></person-group>:
<article-title>Treatment before seizures: new indications for antiepileptic therapy in children with tuberous sclerosis complex.</article-title>
<source/><italic>Epilepsia.</italic>
<year>2007</year>;<volume>48</volume>(<issue>8</issue>):<fpage>1632; author reply 1632</fpage>–<lpage>4</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2007.01178_3.x</pub-id>
<pub-id pub-id-type="pmid">17692054</pub-id></mixed-citation>
</ref>
<ref id="ref-63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Peters</surname><given-names>JM</given-names></name><name><surname>Goyal</surname><given-names>M</given-names></name><etal></etal></person-group>:
<article-title>Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants.</article-title>
<source/><italic>Pediatr Neurol.</italic>
<year>2016</year>;<volume>54</volume>:<fpage>29</fpage>–<lpage>34</lpage>.
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2015.09.013</pub-id>
<!--<pub-id pub-id-type="pmcid">4691569</pub-id>-->
<pub-id pub-id-type="pmid">26498039</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/726049315">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>A</given-names></name><name><surname>MacLean</surname><given-names>C</given-names></name><name><surname>Ploubidis</surname><given-names>GB</given-names></name><etal></etal></person-group>:
<article-title>Intellectual development before and after the onset of infantile spasms: a controlled prospective longitudinal study in tuberous sclerosis.</article-title>
<source/><italic>Epilepsia.</italic>
<year>2014</year>;<volume>55</volume>(<issue>1</issue>):<fpage>108</fpage>–<lpage>16</lpage>.
<pub-id pub-id-type="doi">10.1111/epi.12484</pub-id>
<pub-id pub-id-type="pmid">24417555</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/718237754">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
<ref id="ref-65">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O’ Callaghan</surname><given-names>FJ</given-names></name><name><surname>Edwards</surname><given-names>SW</given-names></name><name><surname>Alber</surname><given-names>FD</given-names></name><etal></etal></person-group>:
<article-title>Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial.</article-title>
<source/><italic>Lancet Neurol.</italic>
<year>2017</year>;<volume>16</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>42</lpage>.
<pub-id pub-id-type="doi">10.1016/S1474-4422(16)30294-0</pub-id>
<pub-id pub-id-type="pmid">27838190</pub-id></mixed-citation>
</ref>
<ref id="ref-66">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilmshurst</surname><given-names>JM</given-names></name><name><surname>Ibekwe</surname><given-names>RC</given-names></name><name><surname>O'Callaghan</surname><given-names>FJ</given-names></name></person-group>:
<article-title>Epileptic spasms - 175 years on: Trying to teach an old dog new tricks.</article-title>
<source/><italic>Seizure.</italic>
<year>2017</year>;<volume>44</volume>:<fpage>81</fpage>–<lpage>6</lpage>.
<pub-id pub-id-type="doi">10.1016/j.seizure.2016.11.021</pub-id>
<pub-id pub-id-type="pmid">27989601</pub-id></mixed-citation>
<note>
<p>
<ext-link ext-link-type="uri" xlink:href="https://f1000.com/prime/727121286">F1000 Recommendation</ext-link>
</p>
</note>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>